Trending: Moderna's Proposed RSV Vaccine Faces Delayed FDA Review
13:53 ET -- Moderna is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The company said that the U.S. Food and Drug Administration won't meet the target action date of May 12 for a decision on its proposed vaccine for respiratory syncytial virus, or RSV. Moderna said the FDA cited administrative constraints for the delay and is working to complete its review by the end of the month, adding that the agency hasn't flagged any issues that would prevent an approval. Dow Jones & Co. owns Factiva. (zaeem.shoaib@wsj.com)
(END) Dow Jones Newswires
May 10, 2024 14:08 ET (18:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now